Research Subaward Agreement Amendment
Exhibit 10.14
[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
| Research Subaward Agreement Amendment | ||||||
|
Pass-through Entity (PTE)
|
Subrecipient
| |||||
| PTE: Yale University | Subrecipient: Miragen Therapeutics, Inc.
| |||||
| Address: Office of Sponsored Projects 25 Science Park – 3rd Floor 150 Munson Street P.O. Box 208327 | Address: 6200 Lookout Road | |||||
| City, State, Zip+4 (Country): New Haven, CT ###-###-####
| City, State, Zip+4 (Country): Boulder, CO 80301
| |||||
| PTE Principal Investigator (PI): [*], MD
| Subrecipient Principal Investigator (PI): Rusty Montgomery, MD | |||||
| PTE Federal Award No: 4UH2HL123886-03 REVISED | FAIN: UH2HL123886 | Federal Awarding Agency: National Heart, Lung, and Blood Institute |
| Project Title: Mir-29 mimicry as a therapy for pulmonary fibrosis
| ||||||
| Subaward Period of Performance: Start Date: 8/19/2016 End Date: 6/30/2017
| Amount Funded This Action: [*] | Amendment No: 3 | Subaward No: M15A12064 (A10747) | |||
| Effective Date of Amendment: 10/27/2016
| FFATA Reporting: Y | |||||
|
Amendment(s) to Original Terms and Conditions This Amendment revises the above-referenced Research Subaward Agreement as follows:
| ||||||
|
● Subaward Period of Performance is extended through June 30, 2017.
● Budget Period is August 19, 2016 to June 30, 2017.
● Authorized Funding for Budget Period is [*].
● Pre-award is authorized for July 1, 2016 to August 18, 2016.
| ||||||
| All other terms and conditions of this Subaward Agreement remain in full force and effect. | ||||||
| By an Authorized Official of Pass-through Entity: | By an Authorized Official of Subrecipient: | |||||||||||
| /s/[*] | [*] | /s/ Jason A. Leverone | 1/23/17 | |||||||||
|
Name: [*] |
Date |
Name: Jason A. Leverone |
Date | |||||||||
| Title: Award Manager
| Title: CFO | |||||||||||
